Vaped Phenanthrene

NCT07134426 | Not Yet Recruiting

• 1 other identifier: 2022LS127
• Study Type: interventional
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

Some people who used to smoke cigarettes continue to be at higher risk of developing lung cancer, even years after quitting. This study will look to see if a specific chemical, phenanthrene, is broken down in the lungs of former smokers through more harmful pathways than never-smokers. If former smokers break down chemicals that enter their lungs through more harmful pathways this might be putting them at higher risk for developing lung cancer even though they quit smoking. This information may help find better ways to prevent or treat cancer in the future. This study is under an IND, but the drug is not being studied; instead, it is being used as a marker for drug metabolism.

Conditions

Non-Smoker; Former Smoker

Keywords

Smoking; Tobacco; Vaping; Former Smoker; Non-Smoker

Outcome Measures

Primary Outcomes (2)

• Urinary Ratio of D10PheT/D9PhOH

  The ratio of D10-phenanthrene tetraol to D9-phenanthrene phenols in the urine will determine how the lung breaks down a class of cancer-causing chemicals called Polycyclic Aromatic Hydrocarbons (PAHs). The higher this ratio the more the lungs break down these chemicals through harmful pathways, which might increase cancer risk. The lower the ratio the more the lung breaks down the chemicals through safer pathways.

  24 hours after vaping phenanthrene

• TNE

  Total nicotine equivalents will be measured in the urine samples to confirm that study participants are not using tobacco or nicotine products.

  Baseline measure

Study Arms (1)

D10-phenanthrene

OTHER

All study participants (Former Daily Smokers and Non-smokers) will be asked to vape D10-phenanthrene to see how their lungs breakdown a class of cancer-causing chemicals known as polycyclic aromatic hydrocarbons \[PAHs\].

Other: D10-phenanthrene

Interventions

D10-phenanthrene OTHER

All study participants (Former Daily Smokers and Non-smokers) will be asked to vape D10-phenanthrene to see how their lungs breakdown a class of cancer-causing chemicals known as polycyclic aromatic hydrocarbons \[PAHs\].

D10-phenanthrene

Eligibility Criteria

• Age: 21 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• \> 21 years of age
• In good physical \& mental health
• In stable physical \& mental health
• Have tried vaping
• Former daily cigarette smokers who quit 1-20 year ago
• Non-smokers who have not used tobacco or nicotine products

You may not qualify if:

• Has any respiratory disease (ex - asthma, COPD, etc...)
• Has/had high blood pressure
• Has/had liver disease
• Has/had cancer
• Has experience negative effects when vaped previously
• Pregnant or nursing

Sponsors & Collaborators

• University of Minnesota: lead

Study Sites (1)

University of Minnesota

Minneapolis, Minnesota, 55455, United States

Location

MeSH Terms

Conditions

Smoking Cessation; Smoking; Vaping

Condition Hierarchy (Ancestors)

Health Behavior; Behavior

Study Officials

• Stephen Hecht

  University of Minnesota

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Nya Jock

CONTACT

612-624-4568; Phe-study@umn.edu

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: All study participants (Former Daily Smokers and Non-smokers) will be asked to vape D10-phenanthrene to see how their lungs breakdown a class of cancer-causing chemicals known as polycyclic aromatic hydrocarbons \[PAHs\].

Study Record Dates

• First Submitted: August 14, 2025
• First Posted: August 21, 2025
• Study Start: April 1, 2026
• Primary Completion (Estimated): September 1, 2027
• Study Completion (Estimated): June 30, 2028
• Last Updated: March 3, 2026

Record last verified: 2026-03

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)